Hypertrophic cardiomyopathy: Sudden cardiac death risk stratification in adults.
作者信息
Jordà Paloma, García-Álvarez Ana
机构信息
Cardiology Department, Institut Clínic Cardiovascular, Hospital Clínic, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
出版信息
Glob Cardiol Sci Pract. 2018 Aug 12;2018(3):25. doi: 10.21542/gcsp.2018.25.
Abstract
摘要
相似文献
1
Hypertrophic cardiomyopathy: Sudden cardiac death risk stratification in adults.
Glob Cardiol Sci Pract. 2018 Aug 12;2018(3):25. doi: 10.21542/gcsp.2018.25.
2
[Risk stratification of sudden death in hypertrophic cardiomyopathy in 2016].
Presse Med. 2016 Oct;45(10):903-910. doi: 10.1016/j.lpm.2016.04.011. Epub 2016 May 24.
3
[Sudden death (V). Identification and treatment of patients with hypertrophic cardiomyopathy at risk of sudden death].
Rev Esp Cardiol. 2000 Jan;53(1):123-30. doi: 10.1016/s0300-8932(00)75069-x.
4
Sudden cardiac arrest in a young patient with hypertrophic cardiomyopathy and zero canonical risk factors: the inherent limitations of risk stratification in hypertrophic cardiomyopathy.
Congenit Heart Dis. 2014 Mar-Apr;9(2):E51-7. doi: 10.1111/chd.12073. Epub 2013 May 7.
5
Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy.
J Cardiovasc Med (Hagerstown). 2006 Sep;7(9):711-3. doi: 10.2459/01.JCM.0000243007.97793.0f.
6
Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
Rev Port Cardiol. 2005 Mar;24(3):407-15.
7
Congenital and hereditary causes of sudden cardiac death in young adults: diagnosis, differential diagnosis, and risk stratification.
Radiographics. 2013 Nov-Dec;33(7):1977-2001. doi: 10.1148/rg.337125073.
8
[Sudden death in hypertrophic obstructive and non-obstructive cardiomyopathy: can it be prevented?].
Schweiz Med Wochenschr. 1997 Apr 12;127(15):623-30.
9
Identification of patients with hypertrophic cardiomyopathy at high risk for sudden death.
Curr Opin Cardiol. 1995 Jan;10(1):9-15. doi: 10.1097/00001573-199501000-00003.
10
Hypertrophic Cardiomyopathy as a Cause of Sudden Cardiac Death in the Young: A Meta-Analysis.
Am J Med. 2016 May;129(5):486-496.e2. doi: 10.1016/j.amjmed.2015.12.027. Epub 2016 Jan 20.
引用本文的文献
1
Importance of Recognizing Hypertrophic Cardiomyopathy in the Preoperative Clinic.
Fed Pract. 2025 Apr;42(4):166-170. doi: 10.12788/fp.0567. Epub 2025 Apr 17.
2
Validation of ACC/AHA and ESC Sudden Cardiac Death Risk Guidelines in Diverse Hypertrophic Cardiomyopathy Cohort: Stratification HCM Study.
Glob Heart. 2024 Dec 17;19(1):94. doi: 10.5334/gh.1380. eCollection 2024.
3
Cardiomyopathy and Sudden Cardiac Death: Bridging Clinical Practice with Cutting-Edge Research.
Biomedicines. 2024 Jul 18;12(7):1602. doi: 10.3390/biomedicines12071602.
4
Comparing long-term outcomes of septal myectomy and mitral valve replacement in hypertrophic cardiomyopathy patients: A retrospective cohort study in Iran.
Health Sci Rep. 2024 Apr 15;7(4):e2045. doi: 10.1002/hsr2.2045. eCollection 2024 Apr.
5
Hypertrophic Cardiomyopathy: Genetic Foundations, Outcomes, Interconnections, and Their Modifiers.
Medicina (Kaunas). 2023 Aug 4;59(8):1424. doi: 10.3390/medicina59081424.
6
Arrhythmic Risk Stratification among Patients with Hypertrophic Cardiomyopathy.
J Clin Med. 2023 May 10;12(10):3397. doi: 10.3390/jcm12103397.
7
Computational analysis of ventricular mechanics in hypertrophic cardiomyopathy patients.
Sci Rep. 2023 Jan 18;13(1):958. doi: 10.1038/s41598-023-28037-w.
8
Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data.
Front Cardiovasc Med. 2022 Mar 15;9:829553. doi: 10.3389/fcvm.2022.829553. eCollection 2022.
9
Shared Molecular Mechanisms of Hypertrophic Cardiomyopathy and Its Clinical Presentations: Automated Molecular Mechanisms Extraction Approach.
Life (Basel). 2021 Aug 3;11(8):785. doi: 10.3390/life11080785.
10
Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state.
Proc Natl Acad Sci U S A. 2021 Jun 15;118(24). doi: 10.1073/pnas.2025030118.
本文引用的文献
1
International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM).
Circulation. 2018 Mar 6;137(10):1015-1023. doi: 10.1161/CIRCULATIONAHA.117.030437. Epub 2017 Nov 30.
2
Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications.
J Cardiovasc Electrophysiol. 2017 May;28(5):531-537. doi: 10.1111/jce.13194. Epub 2017 Mar 31.
3
Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management.
J Am Coll Cardiol. 2017 Feb 21;69(7):761-773. doi: 10.1016/j.jacc.2016.11.063.
4
Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.
JACC Cardiovasc Imaging. 2016 Dec;9(12):1392-1402. doi: 10.1016/j.jcmg.2016.02.031. Epub 2016 Jul 20.
5
Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy.
Am J Cardiol. 2015 Sep 1;116(5):757-64. doi: 10.1016/j.amjcard.2015.05.047. Epub 2015 Jun 4.
6
Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis.
Heart. 2015 Sep;101(17):1406-11. doi: 10.1136/heartjnl-2015-307682. Epub 2015 Jun 9.
7
Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Circ Arrhythm Electrophysiol. 2015 Aug;8(4):829-35. doi: 10.1161/CIRCEP.114.002553. Epub 2015 Apr 28.
8
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Eur Heart J. 2014 Oct 14;35(39):2733-79. doi: 10.1093/eurheartj/ehu284. Epub 2014 Aug 29.
9
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).
Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439. Epub 2013 Oct 14.
10
A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
Heart. 2013 Apr;99(8):534-41. doi: 10.1136/heartjnl-2012-303271. Epub 2013 Jan 22.
Zotero 插件